Exploiting ETH Zurich research, Micreos is working on a clinical platform that enables the targeted killing of unwanted bacteria only.
Micreos, a Netherlands-based endolysin platform developer using research from ETH Zurich, raised €32m ($37.5m) in funding from undisclosed investors yesterday.
Micreos is working on technology that enables the targeted killing of unwanted bacteria only. The approach relies on endolysins – hydrolytic enzymes that can attack specific bacteria while leaving the remainder of the microbiome intact and thus present an advantage over antibiotics.
The technology was developed together with ETH Zurich, although Micreos is not a spinout of the institute.
It will use the money to accelerate the development of its lead assets targeting atopic dermatitis, diabetic wounds and bloodstream infections.
Altria Ventures, the investment arm of cigarette producer Altria, acquired a 5% stake in Micreos in May 2012 in return for an undisclosed amount of money. Micreos subsequently obtained $13.3m from unnamed backers in February 2016.
